JOHANNESBURG – Aspen Pharmacare advised shareholders on Thursday that the company was engaged in discussions with a potential partner in Europe.
The share price rose 0.76 percent on the JSE on Thursday and closed at R104.29.
This was after the South African drugmaker in its interim results announcement on March 7 said it had embarked on a strategic review of its European and South African commercial pharmaceuticals businesses.
The firm has been trying to reduce its debt burden.
Aspen deputy chief executive Gus Attridge in March admitted the group had high debt levels.